Find, Fight and FollowTM .
Progenics develops innovative medicines and other technologies to target and treat cancer. Progenics’ pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA®, 1095, and PSMA TTC), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyL™), and 3) imaging analysis technology. Progenics’ first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant Pharmaceuticals International, Inc.
We plan to further our mission by acquiring and developing oncology assets – companies and/or product candidates – that expand and complement our capabilities in the cancer space. Product candidates outside our core focus will continue to be out-licensed or partnered with motivated drug developers.